Murphy R, Martin K
Eye (Lond). 2024; 39(1):57-68.
PMID: 39516652
PMC: 11733221.
DOI: 10.1038/s41433-024-03441-2.
Flotte T
Am J Respir Crit Care Med. 2024; 210(12):1387-1389.
PMID: 39265185
PMC: 11716029.
DOI: 10.1164/rccm.202408-1516ED.
Lopez-Gordo E, Chamberlain K, Riyad J, Kohlbrenner E, Weber T
Viruses. 2024; 16(3).
PMID: 38543807
PMC: 10975205.
DOI: 10.3390/v16030442.
He X, Fu Y, Ma L, Yao Y, Ge S, Yang Z
Research (Wash D C). 2024; 6:0291.
PMID: 38188726
PMC: 10768554.
DOI: 10.34133/research.0291.
Li L, Vasan L, Kartono B, Clifford K, Attarpour A, Sharma R
Biomedicines. 2023; 11(10).
PMID: 37893099
PMC: 10603849.
DOI: 10.3390/biomedicines11102725.
Delivery of gene editing therapeutics.
Kevadiya B, Islam F, Deol P, Zaman L, Mosselhy D, Ashaduzzaman M
Nanomedicine. 2023; 54:102711.
PMID: 37813236
PMC: 10843524.
DOI: 10.1016/j.nano.2023.102711.
Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec.
Asher D, Dai D, Klimchak A, Sedita L, Gooch K, Rodino-Klapac L
Mol Ther Methods Clin Dev. 2023; 30:474-483.
PMID: 37674905
PMC: 10477757.
DOI: 10.1016/j.omtm.2023.08.002.
Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors.
Williams J, Paez P
Mol Ther Nucleic Acids. 2023; 32:494-503.
PMID: 37346980
PMC: 10280095.
DOI: 10.1016/j.omtn.2023.04.003.
Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs.
Tang Y, Fakhari S, Huntemann E, Feng Z, Wu P, Feng W
Mol Ther Methods Clin Dev. 2023; 29:70-80.
PMID: 36950451
PMC: 10025970.
DOI: 10.1016/j.omtm.2023.02.015.
Adeno-associated virus vector-mediated gene therapy for the treatment of ovarian cancer: a literature review.
Zhu J, Qin T, Wei L, Chen F, Ding Y, Zhang Q
Ann Transl Med. 2022; 10(18):1024.
PMID: 36267784
PMC: 9577757.
DOI: 10.21037/atm-22-4426.
Nucleic Acid Delivery to the Vascular Endothelium.
Reschke M, Piotrowski-Daspit A, Pober J, Saltzman W
Mol Pharm. 2022; 19(12):4466-4486.
PMID: 36251765
PMC: 10673694.
DOI: 10.1021/acs.molpharmaceut.2c00653.
Approaches to Gene Modulation Therapy for ALS.
Meijboom K, Brown R
Neurotherapeutics. 2022; 19(4):1159-1179.
PMID: 36068427
PMC: 9587165.
DOI: 10.1007/s13311-022-01285-w.
Durability of transgene expression after rAAV gene therapy.
Muhuri M, Levy D, Schulz M, McCarty D, Gao G
Mol Ther. 2022; 30(4):1364-1380.
PMID: 35283274
PMC: 9077371.
DOI: 10.1016/j.ymthe.2022.03.004.
AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway.
Liang S, Walkey C, Martinez A, Su Q, Dickinson M, Wang D
Mol Ther. 2021; 30(1):238-243.
PMID: 34695545
PMC: 8753568.
DOI: 10.1016/j.ymthe.2021.10.023.
Gene Therapy for Duchenne Muscular Dystrophy.
Elangkovan N, Dickson G
J Neuromuscul Dis. 2021; 8(s2):S303-S316.
PMID: 34511510
PMC: 8673537.
DOI: 10.3233/JND-210678.
Adeno-Associated Vector-Delivered CRISPR/Cas9 System Reduces Feline Leukemia Virus Production In Vitro.
Helfer-Hungerbuehler A, Shah J, Meili T, Boenzli E, Li P, Hofmann-Lehmann R
Viruses. 2021; 13(8).
PMID: 34452500
PMC: 8402633.
DOI: 10.3390/v13081636.
Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges.
Yoder K, Rabe A, Fishel R, Larue R
Front Mol Biosci. 2021; 8:662331.
PMID: 34055882
PMC: 8149907.
DOI: 10.3389/fmolb.2021.662331.
Evolving AAV-delivered therapeutics towards ultimate cures.
He X, Urip B, Zhang Z, Ngan C, Feng B
J Mol Med (Berl). 2021; 99(5):593-617.
PMID: 33594520
PMC: 7885987.
DOI: 10.1007/s00109-020-02034-2.
Viral vector platforms within the gene therapy landscape.
Bulcha J, Wang Y, Ma H, Tai P, Gao G
Signal Transduct Target Ther. 2021; 6(1):53.
PMID: 33558455
PMC: 7868676.
DOI: 10.1038/s41392-021-00487-6.
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention.
Kisalu N, Pereira L, Ernste K, Flores-Garcia Y, Idris A, Asokan M
JCI Insight. 2020; 6(3).
PMID: 33332286
PMC: 7934869.
DOI: 10.1172/jci.insight.143958.
